<DOC>
	<DOC>NCT01485861</DOC>
	<brief_summary>This multicenter, international, Phase Ib/II trial consists of two stages: a Phase Ib, open-label stage in which the recommended Phase II dose will be determined for ipatasertib and GDC-0980 in combination with abiraterone and prednisone/prednisolone and a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus placebo with abiraterone and prednisone/prednisolone.</brief_summary>
	<brief_title>Study of Ipatasertib or GDC-0980 With Abiraterone Acetate Versus Coralie in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been previously treated with docetaxel and has progressed during treatment of at least one hormonal therapy Two rising PSA levels greater than or equal to (&gt;/=) 2 ng/mL measured &gt;/= 1 week apart or radiographic evidence of disease progression in soft tissue or bone Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening Adequate hematologic and organ function Documented willingness to use an effective means of contraception History of Type I or Type II diabetes mellitus requiring insulin New York Heart Association Class III or IV heart failure or Left ventricular ejection fraction &lt; 50% or ventricular arrhythmia requiring medication Significant atherosclerotic disease, as evidenced by: unstable angina, history of myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident within 6 months prior to Day 1 Active autoimmune disease that is not controlled by nonsteroidal antiinflammatory drugs or active inflammatory disease which requires immunosuppressive therapy Clinically significant history of liver disease History of adrenal insufficiency or hyperaldosteronism Phase II only: Previous therapy for prostate cancer with 17 alphahydroxylase/C17,20lyase inhibitors, including abiraterone Phase II only: Previous treatment for prostate cancer with Protein kinase B phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors Need for chronic corticosteroid therapy of &gt;/= 20 mg of prednisone per day or an equivalent dose of other anti inflammatory corticosteroids or immunosuppressant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>